{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T16:34:13Z","timestamp":1787070853886,"version":"build-2736575974"},"reference-count":28,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"2","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2021,4]]},"abstract":"<jats:sec>\n                    <jats:title>Aim of Study:<\/jats:title>\n                    <jats:p>There is limited information regarding the \u03b1-emitter radiopharmaceuticals dose calculation used in the setting of men with prostate cancer (PCa). The present study investigates the \u03b1-emitter radiopharmaceuticals absorbed dose distribution in the body organs.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Materials and Methods:<\/jats:title>\n                    <jats:p>The \u03b1-emitter radiopharmaceuticals dose coefficient and absorbed doses biokinetics distribution, which are used for the treatment of PCa in all over the world, were performed using the \u201cInternal Dose Assessed by Computer\u201d (IDAC-Dose 2.1) program. The results of absorbed dose distribution in any organ of the body, were compared in studied \u03b1-emitter radiopharmaceuticals.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>\n                      The absorbed dose value of\n                      <jats:sup>223<\/jats:sup>\n                      Ra radiopharmaceutical in the prostate organ was evaluated 9.47E-9 Gy\/Bq. The maximum and minimum absorbed doses due to biokinetics distribution of\n                      <jats:sup>223<\/jats:sup>\n                      Ra were found in the thymus (9.53E-8 Gy\/Bq) and eye lenses (1.30E-10 Gy\/Bq) organs, respectively. Furthermore, the\n                      <jats:sup>225<\/jats:sup>\n                      Ac absorbed dose in the prostate organ was obtained 1.91E-9 Gy\/Bq, where this value is 1% of total body dose. While the absorbed dose distribution of\n                      <jats:sup>225<\/jats:sup>\n                      Ac in body organs shows the highest concentration in the spleen (1.47E-8 Gy\/Bq) and lowest in the eye lenses (7.93E-12 Gy\/Bq).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion:<\/jats:title>\n                    <jats:p>\n                      The absorbed dose in the body organs due to\n                      <jats:sup>223<\/jats:sup>\n                      Ra and\n                      <jats:sup>225<\/jats:sup>\n                      Ac \u03b1-emitter radiopharmaceuticals which are used in metastasized castration-resistant prostate cancer (mCRPC), calculated in this study. The results of this study will assist in evaluating and analyzing human body organ doses from application of\n                      <jats:sup>223<\/jats:sup>\n                      Ra and\n                      <jats:sup>225<\/jats:sup>\n                      Ac that used in mCRPC patients.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.4103\/jcrt.jcrt_892_18","type":"journal-article","created":{"date-parts":[[2020,2,6]],"date-time":"2020-02-06T00:58:02Z","timestamp":1580950682000},"page":"348-352","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":9,"title":["Calculation of radium-223 and actinium-225 \u03b1-emitter radiopharmaceuticals dose rates in treatment of metastatic castration-resistant prostate cancer"],"prefix":"10.4103","volume":"17","author":[{"given":"Akbar","family":"Abbasi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mehdi","family":"Dadashpour","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Iraj","family":"Alipourfard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-7-20241021","doi-asserted-by":"crossref","first-page":"220","DOI":"10.3322\/caac.21149","article-title":"Cancer treatment and survivorship statistics, 2012","volume":"62","author":"Siegel","year":"2012","journal-title":"CA Cancer J Clin"},{"key":"R2-7-20241021","doi-asserted-by":"crossref","first-page":"271","DOI":"10.3322\/caac.21349","article-title":"Cancer treatment and survivorship statistics, 2016","volume":"66","author":"Miller","year":"2016","journal-title":"CA Cancer J Clin"},{"key":"R3-7-20241021","doi-asserted-by":"crossref","first-page":"2532","DOI":"10.1001\/jama.2017.7248","article-title":"The diagnosis and treatment of prostate cancer: A review","volume":"317","author":"Litwin","year":"2017","journal-title":"JAMA"},{"key":"R4-7-20241021","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1007\/s12149-013-0775-8","article-title":"Strontium-89 for prostate cancer with bone metastases: The potential of cancer control and improvement of overall survival","volume":"28","author":"Kuroda","year":"2014","journal-title":"Ann Nucl Med"},{"key":"R5-7-20241021","first-page":"ii","article-title":"Dosimetry-based consideration on remission and relapse after therapy with 223Ra-dichloride in castration-resistant prostate cancer (CRPC) with bone metastases. A case report","volume":"8","author":"Mangano","year":"2018","journal-title":"Diagnostics (Basel"},{"key":"R6-7-20241021","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1038\/pcan.2009.50","article-title":"Bone health and prostate cancer","volume":"13","author":"Saylor","year":"2010","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"R7-7-20241021","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1586\/14737140.2015.999045","article-title":"Radium-223 dichloride: A new paradigm in the treatment of prostate cancer","volume":"15","author":"Anido Herranz","year":"2015","journal-title":"Expert Rev Anticancer Ther"},{"key":"R8-7-20241021","doi-asserted-by":"crossref","first-page":"1371","DOI":"10.1016\/j.addr.2008.04.009","article-title":"Realizing the potential of the actinium-225 radionuclide generator in targeted alpha particle therapy applications","volume":"60","author":"Miederer","year":"2008","journal-title":"Adv Drug Deliv Rev"},{"key":"R9-7-20241021","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/j.eururo.2012.09.008","article-title":"A randomized, double-blind, dose-finding, multicenter, phase 2 study of radium chloride (Ra 223) in patients with bone metastases and castration-resistant prostate cancer","volume":"63","author":"Parker","year":"2013","journal-title":"Eur Urol"},{"key":"R11-7-20241021","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1016\/S1470-2045(14)70183-4","article-title":"Effect of radium-223 dichloride on symptomatic skeletal events in patients with castration-resistant prostate cancer and bone metastases: Results from a phase 3, double-blind, randomised trial","volume":"15","author":"Sartor","year":"2014","journal-title":"Lancet Oncol"},{"key":"R12-7-20241021","doi-asserted-by":"crossref","first-page":"1304","DOI":"10.2967\/jnumed.115.157123","article-title":"A phase 1, open-label study of the biodistribution, pharmacokinetics, and dosimetry of 223Ra-dichloride in patients with hormone-refractory prostate cancer and skeletal metastases","volume":"56","author":"Chittenden","year":"2015","journal-title":"J Nucl Med"},{"key":"R13-7-20241021","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1177\/1756287216629870","article-title":"Clinical experience with radium-223 in the treatment of patients with advanced castrate-resistant prostate cancer and symptomatic bone metastases","volume":"8","author":"Hague","year":"2016","journal-title":"Ther Adv Urol"},{"key":"R15-7-20241021","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1007\/s11912-015-0495-4","article-title":"Radionuclide therapies in prostate cancer: Integrating radium-223 in the treatment of patients with metastatic castration-resistant prostate cancer","volume":"18","author":"Nilsson","year":"2016","journal-title":"Curr Oncol Rep"},{"key":"R17-7-20241021","doi-asserted-by":"crossref","first-page":"44131","DOI":"10.18632\/oncotarget.17311","article-title":"Radium-223 for primary bone metastases in patients with hormone-sensitive prostate cancer after radical prostatectomy","volume":"8","author":"Wenter","year":"2017","journal-title":"Oncotarget"},{"key":"R18-7-20241021","doi-asserted-by":"crossref","first-page":"97S","DOI":"10.2967\/jnumed.115.170167","article-title":"PSMA-based radioligand therapy for metastatic castration-resistant prostate cancer: The Bad Berka experience since 2013","volume":"57","author":"Kulkarni","year":"2016","journal-title":"J Nucl Med"},{"key":"R19-7-20241021","first-page":"262","article-title":"330.223Ra therapy of bone metastases for castration-resistant prostate cancer (CRPC): Lesion dosimetry and follow-up for a large group of patients","volume":"56","author":"Pacilio","year":"2018","journal-title":"Phys Med Eurean J Med Phys"},{"key":"R20-7-20241021","doi-asserted-by":"crossref","first-page":"1671","DOI":"10.1007\/s00259-017-3756-7","article-title":"Practical recommendations for radium-223 treatment of metastatic castration-resistant prostate cancer","volume":"44","author":"Du","year":"2017","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"R21-7-20241021","doi-asserted-by":"crossref","first-page":"6250s","DOI":"10.1158\/1078-0432.CCR-06-0841","article-title":"High-linear energy transfer irradiation targeted to skeletal metastases by the alpha-emitter 223Ra: Adjuvant or alternative to conventional modalities?","volume":"12","author":"Bruland","year":"2006","journal-title":"Clin Cancer Res"},{"key":"R22-7-20241021","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1056\/NEJMoa1213755","article-title":"Alpha emitter radium-223 and survival in metastatic prostate cancer","volume":"369","author":"Parker","year":"2013","journal-title":"N Engl J Med"},{"key":"R23-7-20241021","doi-asserted-by":"crossref","first-page":"1233","DOI":"10.1182\/blood.V100.4.1233.h81602001233_1233_1239","article-title":"Targeted alpha particle immunotherapy for myeloid leukemia","volume":"100","author":"Jurcic","year":"2002","journal-title":"Blood"},{"key":"R24-7-20241021","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1097\/00006231-199302000-00009","article-title":"The feasibility of 225Ac as a source of alpha-particles in radioimmunotherapy","volume":"14","author":"Geerlings","year":"1993","journal-title":"Nucl Med Commun"},{"key":"R25-7-20241021","first-page":"103","article-title":"Radiosensitivity of prostate cancer cell lines for irradiation from beta particle-emitting radionuclide177 Lu compared to alpha particles and gamma rays","volume":"36","author":"Elgqvist","year":"2016","journal-title":"Anticancer Res"},{"key":"R26-7-20241021","first-page":"222","article-title":"Radium-223 chloride: Radiation safety, tolerability, and survival gain in patients with castration-resistant prostate cancer (CRPC) and bone metastases","volume":"53","author":"Lewington","year":"2012","journal-title":"J Nucl Med"},{"key":"R27-7-20241021","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1007\/s00259-012-2265-y","article-title":"Dosimetry of 223 Ra-chloride: Dose to normal organs and tissues","volume":"40","author":"Lassmann","year":"2013","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"R28-7-20241021","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1186\/s13550-017-0339-3","article-title":"IDAC-dose 2.1, an internal dosimetry program for diagnostic nuclear medicine based on the ICRP adult reference voxel phantoms","volume":"7","author":"Andersson","year":"2017","journal-title":"EJNMMI Res"},{"key":"R29-7-20241021","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1177\/0146645316661077","article-title":"ICRP publication 133: The ICRP computational framework for internal dose assessment for reference adults: Specific absorbed fractions","volume":"45","author":"Bolch","year":"2016","journal-title":"Ann ICRP"},{"key":"R30-7-20241021","first-page":"7","article-title":"ICRP publication 107.Nuclear decay data for dosimetric calculations","volume":"38","author":"Eckerman","year":"2008","journal-title":"Ann ICRP"},{"key":"R31-7-20241021","doi-asserted-by":"crossref","first-page":"42","DOI":"10.4103\/jcrt.JCRT_183_17","article-title":"Effect of Au-197 nanoparticles along with Sm-153 radiopharmaceutical in prostate cancer from simulation method","volume":"15","author":"Abbasi","year":"2019","journal-title":"J Cancer Res Ther"}],"container-title":["Journal of Cancer Research and Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.4103\/jcrt.JCRT_892_18","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T15:37:43Z","timestamp":1787067463000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.4103\/jcrt.JCRT_892_18"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,4]]},"references-count":28,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2021]]}},"URL":"https:\/\/doi.org\/10.4103\/jcrt.jcrt_892_18","relation":{},"ISSN":["0973-1482"],"issn-type":[{"value":"0973-1482","type":"print"}],"subject":[],"published":{"date-parts":[[2021,4]]}}}